Vyne Therapeutics Inc
$ 0.66
0.94%
11 Jun - close price
- Market Cap 22,176,300 USD
- Current Price $ 0.66
- High / Low $ 0.67 / 0.66
- Stock P/E N/A
- Book Value 0.74
- EPS -0.51
- Next Earning Report -
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.37 %
- ROE -0.63 %
- 52 Week High 1.96
- 52 Week Low 0.28
About
VYNE Therapeutics Inc., a pharmaceutical company, focuses on developing and commercializing various therapies for dermatology. The company is headquartered in Bridgewater, New Jersey.
Analyst Target Price
$2.00
Quarterly Earnings
| Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-05-15 | 2026-03-12 | 2025-11-06 | 2025-08-14 | 2025-05-08 | 2025-03-06 | 2024-11-07 | 2024-08-14 | 2024-05-09 | 2024-02-29 | 2023-11-13 | 2023-08-14 |
| Reported EPS | -0.0838 | -0.11 | -0.17 | -0.13 | -0.2 | -0.2822 | -0.29 | -0.22 | -0.15 | -0.2 | -2.01 | -3.09 |
| Estimated EPS | None | -0.23 | -0.13 | -0.22 | -0.29 | -0.3033 | -0.23 | -0.19 | -0.24 | -0.5 | -0.76 | -2.58 |
| Surprise | 0 | 0.12 | -0.04 | 0.09 | 0.09 | 0.0211 | -0.06 | -0.03 | 0.09 | 0.3 | -1.25 | -0.51 |
| Surprise Percentage | None% | 52.1739% | -30.7692% | 40.9091% | 31.0345% | 6.9568% | -26.087% | -15.7895% | 37.5% | 60% | -164.4737% | -19.7674% |
Next Quarterly Earnings
| Reported Date |
| Fiscal Date Ending |
| Estimated EPS |
| Currency |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: VYNE
2026-06-02 20:40:23
VYNE Therapeutics Inc. reported insider trading activity where President and CEO David Domzalski acquired 30,791 shares of common stock at $0.31 per share through the company's employee share purchase plan (ESPP) on May 29, 2026. This transaction increased his direct holdings to 438,779 shares. The shares were purchased at 85% of the fair market value on December 1, 2025, and represent the maximum allowed under the plan for the calendar year.
2026-05-21 20:40:43
VYNE Therapeutics Inc. reported details of a planned reverse merger with Yarrow Bioscience, where Yarrow will become the dominant entity, trading as NASDAQ: YARW after an expected Q3 2026 close. Yarrow's investor presentation highlights its lead antibody YB-101 for Graves' disease and thyroid eye disease, with Phase 2 development plans starting in Q2 2026 and FDA Fast Track status. Yarrow has raised approximately $200 million, including expected pre-closing financing, providing a cash runway into 2028.
2026-05-21 20:40:43
VYNE announced that Yarrow Bioscience will advance YB-101 into Phase 2 for Graves’ disease in Q2 2026, with a Phase 2a readout anticipated in H2 2027. The company has successfully raised $200 million, including expected pre-closing financing, which is expected to fund operations until 2028. This move follows positive Phase 1 results for YB-101 in TED, which showed favorable safety and dose-dependent pharmacodynamic effects.
2026-05-19 13:40:48
This article reports a significant 38.46% decrease in the price target for VYNE Therapeutics (VYNE), bringing it down to $2.04. The information indicates a notable change in analyst expectations for the company's stock performance.
2026-05-15 20:38:48
Nantahala Capital Management, LLC, along with its managing members Wilmot B. Harkey and Daniel Mack, has reported a beneficial ownership of 2,000,000 shares of VYNE Therapeutics Inc. common stock, representing 6.00% of the class. This stake was acquired for investment purposes and gives the reporting persons shared voting and dispositive power over the shares, as detailed in their Schedule 13G filing with the SEC as of March 31, 2026. The filing emphasizes that the acquisition was in the ordinary course of business and not aimed at changing or influencing the control of the issuer.
2026-05-15 19:38:48
VYNE Therapeutics reported a narrowed net loss in Q1 2026, stemming from reduced R&D expenses as it winds down its BET inhibitor programs. The company plans to merge with Yarrow Bioscience, Inc., a privately held biotechnology company, with the merger expected to close in Q3 2026 and securing $200 million in financing ($100 million Series A and $100 million pre-closing financing). VYNE also expects to pay a special cash dividend of $14.5–$16.5 million to existing stockholders prior to the merger's completion.
